Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of daratumumab added to VMP in multiple myeloma
2014-002272-88Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Aug 2014
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of daratumumab and bortezomib in multiple myeloma (MM) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Started Aug 2014; status: completed.
02
Drugs
daratumumabbortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2014-002272-88.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002272-88.